Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia

by Seiichiro Katagiri, Tetsuzo Tauchi, Keiko Ando, Seiichi Okabe, Moritaka Gotoh, Kazuma Ohyashiki
Published 2017-01-01

Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.

by Seiichi Okabe, Tetsuzo Tauchi, Shinya Kimura, Taira Maekawa, Toshihiko Kitahara, Yoko Tanaka, Kazuma Ohyashiki
Published 2014-01-01

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib

by Kazuma Ohyashiki, Tomohiro Umezu, Seiichiro Katagiri, Chiaki Kobayashi, Kenko Azuma, Tetsuzo Tauchi, Seiichi Okabe, Yutaka Fukuoka, Junko H. Ohyashiki
Published 2016-04-01